PAH Human Gene Knockout Kit (CRISPR)

CAT#: KN204694RB

PAH - human gene knockout kit via CRISPR, HDR mediated




 HDR-mediated knockout kit validation

  See Other Versions

CNY 12,260.00


货期*
6周

规格
    • 1 kit

Product images

经常一起买 (3)
pCAS-Scramble, pCas-Guide vector with a scrambled sequence as a negative control (10 µg)
    • 10 ug

CNY 3,710.00


PAH mouse monoclonal antibody,clone OTI4F6
    • 100 ul

CNY 1,999.00
CNY 3,600.00


PAH (Myc-DDK-tagged)-Human phenylalanine hydroxylase (PAH)
    • 10 ug

CNY 3,656.00
CNY 3,990.00

Specifications

Product Data
Format 2 gRNA vectors, 1 RFP-BSD donor, 1 scramble control
Donor DNA RFP-BSD
Symbol PAH
Locus ID 5053
Kit Components

KN204694G1, PAH gRNA vector 1 in pCas-Guide CRISPR vector

KN204694G2, PAH gRNA vector 2 in pCas-Guide CRISPR vector

KN204694RB-D, donor DNA containing left and right homologous arms and RFP-BSD functional cassette.

GE100003, scramble sequence in pCas-Guide vector

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.
Reference Data
RefSeq NM_000277, NM_001354304
Synonyms PH; PKU; PKU1
Summary This gene encodes a member of the biopterin-dependent aromatic amino acid hydroxylase protein family. The encoded phenylalanine hydroxylase enzyme hydroxylates phenylalanine to tyrosine and is the rate-limiting step in phenylalanine catabolism. Deficiency of this enzyme activity results in the autosomal recessive disorder phenylketonuria. [provided by RefSeq, Aug 2017]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...